Search
Search | Sitemap Contact Sign Up

Hikma Pharmaceuticals USA Inc. v. Vanda Pharmaceuticals Inc.

 
DOCKET NO.
18-817
OP. BELOW
Fed. Cir.
SUBJECT
Patent

Question(s) Presented

“The question presented is whether patents that claim a method of medically treating a patient automatically satisfy Section 101 of the Patent Act, even if they apply a natural law using only routine and conventional steps.”

Posts About this Case

Date
Proceedings and Orders
October 26, 2018
Application (18A461) to extend the time to file a petition for a writ of certiorari from November 12, 2018 to December 27, 2018, submitted to The Chief Justice.
October 31, 2018
Application (18A461) granted by The Chief Justice extending the time to file until December 27, 2018.
December 27, 2018
Petition for a writ of certiorari filed. (Response due January 28, 2019)
January 22, 2019
Motion to extend the time to file a response from January 28, 2019 to February 12, 2019, submitted to The Clerk.
January 23, 2019
Motion to extend the time to file a response is granted and the time is extended to and including February 12, 2019.
January 28, 2019
Brief amici curiae of Intellectual Property and Innovation Professors, Engine Advocacy, et al. filed.
January 28, 2019
Brief amici curiae of The Association for Accessible Medicines and Certain Individual Companies filed.
February 12, 2019
Brief of respondent Vanda Pharmaceuticals USA, Inc. in opposition filed.
February 26, 2019
Reply of petitioners Hikma Pharmaceuticals USA Inc., et al. filed.
February 27, 2019
DISTRIBUTED for Conference of 3/15/2019.
March 15, 2019
Letter of Hikma Pharmaceuticals USA Inc., et al. received.
March 18, 2019
The Solicitor General is invited to file a brief in this case expressing the views of the United States.
May 22, 2019
Amendment to Rule 29.6 Corporate Disclosure Statement filed with respect to brief in opposition of respondent Vanda Pharmaceuticals Inc.
December 6, 2019
Amicus brief of United States submitted.
December 20, 2019
Supplemental Brief of Hikma Pharmaceuticals USA Inc., et al. submitted.
December 23, 2019
DISTRIBUTED for Conference of 1/10/2020.
December 26, 2019
Supplemental Brief of Vanda Pharmaceuticals USA, Inc. submitted.
December 26, 2019
Letter of December 26, 2019 from counsel for petitioner received. (Distributed)
January 13, 2020
Petition DENIED.